• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

CVS Health, Aetna Tackle High Knee Replacements

Article

In an effort to reduce readmissions and costs, CVS Health has launched a program to help patients with knee replacements.

Knee pain

CVS Health announced a pilot program designed to improve outcomes for knee replacement patients.

The program, in concert with CVS Health’s recently-purchased Aetna, will allow patients to meet with case managers at select CVS locations to discuss potential sticking points. These include making sure a surgeon is in network or performing a home assessment.

Aetna spokesperson Ethan Slavin says the program could lead to better outcomes and lower costs: “We believe that this program can create an improved experience for members going through knee replacement and improve health outcomes over time. Avoiding hospital readmission, especially after surgery, can also result in significant medical cost savings.

Slavin says that the program will hopefully help patients both better prepare for surgery and recover after.

While there aren’t currently plans for expanding the program, Slavin says it’s something the company is exploring, possibly even including other conditions.

Related Videos
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
Video 3 - "Harnessing Prescription Drug Therapeutics as Monotherapy and Adjunct Therapy"
Related Content
© 2024 MJH Life Sciences

All rights reserved.